Devin Effinger, PhD
@devin_effinger
Followers
3K
Following
4K
Media
136
Statuses
605
Postdoc at @cuanschutz researching #psychedelics | lived experience of TBI & SUD #recovery | Board member, @winter_brain
Boulder, CO
Joined December 2020
It’s wild how much change is possible in this life. From relearning to talk post-TBI, to full blown heroin addiction, to a life beyond anything I could have imagined. Im very fortunate to not only be alive, but to have been selected to speak at 2025 TEDxBoulder!
5
9
60
If anyone is looking (or know of someone) for a roommate and has a spot at the Atlantis for @ACNPorg , please let me know!
0
5
3
Devin Effinger @devin_effinger and @MelissaHerman4 argue that, though many human psychedelic clinical trials are underway, preclinical studies remain our best bet to answer fundamental questions about the neurobiology of psychedelics. https://t.co/4HBcJSMtnK
thetransmitter.org
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering…
0
12
24
What an honor! Humbled and grateful. It was a beautiful disaster and a perfect metaphor for my recovery ending with a standing ovation. Thank you so much to the organizers and stay tuned for the link! @TEDxBoulder
1
5
15
Takeaway: In mice, 8 weeks of low-dose LSD produced no evidence of heart damage. But human studies are still essential — especially in people with cardiovascular risk factors.
0
0
2
Pharmacokinetic modeling gave us a potential explanation: 👉 Fenfluramine is still present in blood at 24h, leading to sustained and chronic 5-HT2B activation. 👉 Low doses of LSD and psilocin are both off the receptor within 8-10h.
2
0
2
We tested this by giving mice low-dose LSD (microdoses) 5 days per week for 8 weeks and tracked heart structure and function with echocardiography. 🫀 Serotonin & fenfluramine (positive controls) led to ventricular or valvular remodeling. 🫀 LSD had no effects.
1
0
1
🚨 New paper 🚨 For years, there has been concern that psychedelics might pose cardiovascular risks due to their agonist activity at the 5-HT2B receptor — the same target linked to drug-induced heart disease. https://t.co/PsDxP24wKT
pubs.acs.org
Microdosing, the prolonged ingestion of psychedelics at subhallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT2B...
3
11
44
@ACNPorg brought @UmaRChatterjee
@devin_effinger & me together last year: After finding each other on X-as we are all public/open about our lived experience -we met and discussed the ideas for this Study Group! Looking forward to doing this work together@ #ACNP2026🧠❤️💥‼️
THRILLED to share @ACNPorg news x2! 1) Our study group—“Centering Lived Experience in Psychiatric Neuroscience Research: Challenges, Opportunities, & Calls to Action” @EricJNestler @BStaglin @SchumerMaya @devin_effinger @viscidula @noelvest @MichaelECahill1=ACCEPTED! 🤩#ACNP2026
1
11
22
THRILLED to share @ACNPorg news x2! 1) Our study group—“Centering Lived Experience in Psychiatric Neuroscience Research: Challenges, Opportunities, & Calls to Action” @EricJNestler @BStaglin @SchumerMaya @devin_effinger @viscidula @noelvest @MichaelECahill1=ACCEPTED! 🤩#ACNP2026
2
7
24
🚨 New preprint alert! Intranasal esketamine helps with treatment-resistant depression—but do sex differences shape who responds best, and how? We analyzed 5 RCTs and found striking sex-specific symptom patterns. 👉 https://t.co/lr5yWi6qlm
#Depression #Esketamine
medrxiv.org
Background Racemic ketamine and its enantiomer, esketamine, have emerged as fast-acting antidepressant options for individuals with treatment-resistant depression (TRD). Yet, despite growing clinical...
2
6
11
The inaugural #GRCPsychedelics was a success! I am honored to have been one of a few chosen to receive a travel award and be able to share the stage with the leaders in the field. Very grateful to the organizers. 🙏 @kwanalexc @VVyazovskiy @MelissaHerman4 @ViditaVaidya
0
5
25
Save the date for Psychedelics GRC ***2029***!!
We worked so well as a team for the #GRCPsychedelics @VVyazovskiy @MelissaHerman4 @ViditaVaidya and congrats to @TheBorisLab and @MikaelPalner, who will be the future vice-chairs!
3
10
59
I had deactivated my account out of a sense of mental preservation, and was planning to log back in every 29 days to preserve my history and connections, but I apparently failed at that task. I'm now slowly rebuilding my twitter network.
1
2
9
Come meet @camri_unc members during @ISMRM! On Saturday (May 10) at the @bruker event and Monday (May 12) at 14:01 in the fMRI power pitch session, @TzuHaoHarryChao will talk about his work mapping inter-brain functional connectivity in socially interacting mice using SORDINO.
1
6
21
It’s a common misconception that, for the person with a SUD, the substances are the problem. In my experience, the real problem was much deeper. Until I addressed the underlying causes/conditions, longterm sobriety was unattainable. Link in bio. #sober #sobriety #RecoveryPosse
2
5
25
Honored and excited to present my work at the Rising Stars in Neuroscience Symposium! Grateful to @EricJNestler, @SinaiBrain and @UUNeurobiology for this opportunity — can’t wait to share what I’ve been working on!
👏Congratulations to the #NestlerLab's @GylesTrevonn on being selected as a Rising Star in Neuroscience! On May 19👉DON'T MISS the Rising Stars in Neuroscience Symposium Presented by Department of Neurobiology @universityofutah. RSVP: https://t.co/Cqg94ntfrF or scan the QR code
3
6
36
i'm just a senior postdoc, standing in front of a career that i have worked really hard for, asking higher education in the united states to not completely implode in front of my eyes before i even get a chance to say the words 'my lab studies'
26
123
2K
We're recruiting a new therapist(s) for ongoing & upcoming clinical trials with psilocybin-assisted psychotherapy at @UCalgary & @HotchkissBrain Come join our diverse, growing @pact_lab team exploring evidence-based psychedelic interventions! Ad here: https://t.co/3VfHWTobDL
2
12
11